Latest filings (excl ownership)
15-12B
Securities registration termination
31 Dec 18
EFFECT
Notice of effectiveness
27 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Dec 18
POSASR
Automatic shelf registration (post-effective amendment)
21 Dec 18
8-K
Completion of Acquisition or Disposition of Assets
21 Dec 18
25-NSE
Exchange delisting
21 Dec 18
POS AM
Prospectus update (post-effective amendment)
20 Dec 18
8-K
Other Events
17 Dec 18
DEFA14A
Additional proxy soliciting materials
12 Dec 18
8-K
Other Events
3 Dec 18
DEFM14A
Proxy related to merger
16 Nov 18
DEFA14A
Additional proxy soliciting materials
8 Nov 18
10-Q
2018 Q3
Quarterly report
8 Nov 18
8-K
Endocyte Provides Third Quarter 2018 Financial Results and Operational Update
7 Nov 18
DFAN14A
Additional proxy materials by non-management
6 Nov 18
DFAN14A
Additional proxy materials by non-management
5 Nov 18
PREM14A
Preliminary proxy related to merger
31 Oct 18
DEFA14A
Additional proxy soliciting materials
19 Oct 18
DFAN14A
Additional proxy materials by non-management
18 Oct 18
DFAN14A
Additional proxy materials by non-management
18 Oct 18
DFAN14A
Additional proxy materials by non-management
18 Oct 18
DFAN14A
Additional proxy materials by non-management
18 Oct 18
DEFA14A
Additional proxy soliciting materials
18 Oct 18
8-K
Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion
18 Oct 18
DEFA14A
Additional proxy soliciting materials
18 Oct 18
424B5
Prospectus supplement for primary offering
12 Sep 18
8-K
Entry into a Material Definitive Agreement
12 Sep 18
424B5
Prospectus supplement for primary offering
10 Sep 18
8-K
Demonstrating benefit in rPFS versus control, with no detriment to OS, sufficient for full approval
10 Sep 18
S-3ASR
Automatic shelf registration
10 Sep 18
CT ORDER
Confidential treatment order
10 Aug 18
10-Q
2018 Q2
Quarterly report
1 Aug 18
8-K
Endocyte Provides Second Quarter 2018 Financial Results and Operational Update
31 Jul 18
CT ORDER
Confidential treatment order
19 Jul 18
Latest ownership filings
SC 13G/A
Endocyte Inc
14 Feb 19
4
FRED A MIDDLETON
21 Dec 18
4
Patrick Machado
21 Dec 18
4
David R. McAvoy
21 Dec 18
4
Christopher P Leamon
21 Dec 18
4
Alison A. Armour
21 Dec 18
4
Katherine Parker
21 Dec 18
4
Lesley Russell
21 Dec 18
4
Erik C. Chelius
21 Dec 18
4
JOHN C APLIN
21 Dec 18
4
Beth Taylor
21 Dec 18
4
COLIN GODDARD
21 Dec 18
4
Dawn Svoronos
21 Dec 18
4
MARC D KOZIN
21 Dec 18
4
Michael A. Sherman
21 Dec 18
4
Philip S Low
21 Dec 18
4
Michael T. Andriole
21 Dec 18
4
Beth Taylor
19 Dec 18
4
Christopher P Leamon
19 Dec 18
4
Michael T. Andriole
19 Dec 18
4
Alison A. Armour
19 Dec 18
4
Michael A. Sherman
19 Dec 18
4
Philip S Low
19 Dec 18
3
David R. McAvoy
15 Nov 18
SC 13D
Endocyte Inc
1 Nov 18
4/A
Philip S Low
16 Oct 18
4/A
Katherine Parker
16 Oct 18
4/A
Christopher P Leamon
16 Oct 18
4
Alison A. Armour
9 Oct 18
4
Christopher P Leamon
9 Oct 18
4
Beth Taylor
9 Oct 18
4
Michael A. Sherman
9 Oct 18
4
Michael T. Andriole
9 Oct 18
4
Erik C. Chelius
9 Oct 18
4
Katherine Parker
9 Oct 18
4
Philip S Low
9 Oct 18
4
Christopher P Leamon
29 Aug 18
4
Beth Taylor
29 Aug 18
4
Beth Taylor
22 Aug 18
4
Alison A. Armour
2 Aug 18